-
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc
Group sales were +6% at constant exchange rates (CER)1, -2% when reported in CHF and +8% in USD2, in the first six months, driven by high demand for innovative medicines and diagnostics. Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales…
-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470
Press Release Nicox Announces Positive Pre-submission Regulatory Feedback in China Supporting NDA filing for NCX 470 Exclusive licensee for China, Ocumension, received positive pre-submission regulatory feedback from the Chinese Center for Drug Evaluation (CDE) for NCX 470 Based on this feedback, Ocumension intends to proceed with the New Drug Application (NDA) submission in China Submission…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.
